US Judge invalidates blood glucose sensor patent, opens door for Apple Watch

Case outcome and scope

• Commenters note that 12 of 23 claims were invalidated as “obvious” over prior art; the rest were found not to cover Apple’s specific implementation under an alternative claim construction.
• This is seen as opening a path for Apple’s approach, but people expect others will still need patent counsel to avoid new IP minefields.
• The patent is described as conceptually very close to pulse oximetry, with some surprise that such incremental work survived as long as it did.

Obviousness and patent quality

• Several posts highlight how “obvious in hindsight” strongly biases juries: once an invention is clearly explained, it feels trivial even when top R&D teams previously failed to solve it.
• Others point out that the legal notion of “obvious” is narrow: it must be obvious to a “person of ordinary skill” at the time of filing, and in practice it’s hard to reject claims on that basis.

Patent system: abolition vs reform

• One camp calls patents “regressive” tools of large corporations that shackle small innovators, create artificial scarcity, and should be abolished. They cite litigation cost, patent trolls, and historical examples of patents blocking whole industries.
• Another camp argues patents still matter: long R&D cycles, tooling costs, and investor expectations rely on enforceable IP; standard-essential patents under FRAND are given as an example of patents enabling interoperability.
• There’s dispute over first-to-file: some claim it lets big firms “steal” inventions; others explain that you must still be the actual inventor and that first-to-file mainly simplifies priority disputes.
• Several argue the original intent was to force public disclosure and build a technical commons, but modern practice (vague software patents, broad claims) has drifted far from that ideal.

Patents vs copyright and trademarks

• Many call patents more harmful than copyright: patents can block entire problem domains, while copyright only protects specific expressions.
• Suggestions include shorter, more expensive-to-renew copyright terms and either sharply limited patents or eliminating them outside domains like pharmaceuticals.
• There’s debate over whether algorithms are math (thus non-patentable) or inventions, and whether design patents further blur patent/copyright boundaries.

Non‑invasive glucose on wearables

• Multiple commenters stress non-invasive glucose sensing is a “holy grail” with decades of failed attempts, especially via spectroscopy; skin properties, fitness, and physiological changes introduce huge noise.
• Consensus: even if Apple ships something, it will likely be good for trends (how your body responds to food, exercise, and prediabetes screening), not safe enough for insulin dosing.
• Diabetics and prediabetics in the thread say even coarse, trend-only data and alerts would be life-changing; clinicians and device builders caution against relying on such data for therapy.
• Some see a large “wellness” and athletic market (endurance training, keto, chronic disease risk), though others think most users won’t meaningfully change behavior despite more metrics.

Related IP tangents

• The Masimo blood-oxygen dispute is noted as a separate, still-contested issue affecting some Apple Watch models.
• E‑ink and other long-lived patents are cited as examples where expiry or invalidation could unlock cheaper, more widespread hardware.